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Abstract: Background: The epidemiologic utility of STARHS hinges not only on producing accurate estimates of HIV 
incidence, but also on identifying risk factors for recent HIV infection. 
Methods: As part of an HIV seroincidence study, 800 Rwandan female sex workers (FSW) were HIV tested, with those 
testing positive further tested by BED-CEIA (BED) and AxSYM Avidity Index (Ax-AI) assays. A sample of HIV-
negative (N=397) FSW were followed prospectively for HIV seroconversion. We compared estimates of risk factors for: 
1) prevalent HIV infection; 2) recently acquired HIV infection (RI) based on three different STARHS classifications 
(BED alone, Ax-AI alone, BED/Ax-AI combined); and 3) prospectively observed seroconversion. 
Results: There was mixed agreement in risk factors between methods. HSV-2 coinfection and recent STI treatment were 
associated with both prevalent HIV infection and all three measures of recent infection. A number of risk factors were 
associated only with prevalent infection, including widowhood, history of forced sex, regular alcohol consumption, prior 
imprisonment, and current breastfeeding. Number of sex partners in the last 3 months was associated with recent infection 
based on BED/Ax-AI combined, but not other STARHS-based recent infection outcomes or prevalent infection. Risk 
factor estimates for prospectively observed seroconversion differed in magnitude and direction from those for recent 
infection via STARHS. 
Conclusions: Differences in risk factor estimates by each method could reflect true differences in risk factors between the 
prevalent, recently, or newly infected populations, the effect of study interventions (among those followed prospectively), 
or assay misclassification. Similar investigations in other populations/settings are needed to further establish the 
epidemiologic utility of STARHS for identifying risk factors, in addition to incidence rate estimation. 
Keywords: HIV/AIDS, incidence, cross-sectional surveys, prospective studies, risk factors, Rwanda. 
INTRODUCTION 
 Reliable information on HIV incidence is critical to 
public health practitioners and policymakers working in HIV 
prevention in order to identify target populations, evaluate 
the impact of HIV prevention interventions, and identify 
important trends in dynamic epidemics [1]. Data on risk 
factors for incident HIV infection help identify at-risk sub-
groups in immediate need of primary prevention 
interventions [2, 3]. Despite these important applications, 
data on HIV incidence rates and risk factors are scant,  
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especially in sub-Saharan Africa where the majority of new 
HIV infections are occurring [4, 5], and where most 
information on risk factors is derived from HIV prevalence 
data, such as from the Demographic and Health Surveys 
(DHS) [6]. Key public health agencies, including the World 
Health Organization and US Centers for Disease Control and 
Prevention, have begun recommending strengthening of HIV 
incidence surveillance systems at the country and regional 
levels [7-11]. 
 The Serologic Testing Algorithm for Recent HIV 
Seroconversion (STARHS) is a laboratory test-based 
approach that offers a promising alternative to prospective 
incidence measurement for incidence surveillance. 
Laboratory assays used under STARHS, such as the BED-
CEIA (BED) [12] and AxSYM Avidity Index method (Ax-
AI) [13], exploit immunologic properties of early HIV 
infection, such as development of HIV antibodies, to 
distinguish recent infections (RI) from long-term infections 
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(LTI) in HIV-positive persons, enabling estimation of 
incidence in a cross-sectional sample of HIV-positive and 
negative individuals [9, 10, 14-24]. Further, if demographic 
and behavioral data are collected alongside biologic samples 
for STARHS testing, risk factors for RI, as distinguished 
from prevalent infection, can be identified. 
 The potential public health impact of the STARHS 
method lies in its epidemiologic utility, which we define as 
the ability of an assay or algorithm to: 1) accurately estimate 
HIV incidence rates, and 2) distinguish risk factors for RI 
from LTI when such differences exist, within a population 
sample of individuals tested for HIV and interviewed for 
behavioral and other risk factor information. The latter is 
particularly useful when factors associated with HIV 
transmission and acquisition shift over time, such that groups 
currently at risk for infection (eventual “incident cases”) 
have different behavioral, demographic or other 
characteristics from those with LTI [25, 26]. To date, few 
studies have evaluated STARHS from the perspective of 
epidemiologic utility. Instead, studies have focused on 
assessing assay validity, concluding that STARHS assays 
tend to misclassify certain individuals with LTI as RI [12, 
17, 27-36]. At the population level, this often results in an 
overestimation of HIV incidence rates relative to 
prospectively observed seroconversion rates [18]. However, 
from an epidemiologic standpoint, a certain degree of 
assay/outcome misclassification may be less problematic. 
For example, an assay or algorithm that misclassifies certain 
individuals and overestimates HIV incidence can still be 
considered epidemiologically useful if associations and 
inference related to risk factors are not appreciably altered. 
 We conducted a combined cross-sectional survey (with 
STARHS testing) and prospective cohort study of female sex 
workers (FSW) at Projet Ubuzima in Kigali, Rwanda. An in-
depth analysis of the validity of STARHS-based incidence 
estimates in this population was reported separately, and 
found that HIV incidence rate estimates derived via the BED 
assay alone and BED combined with Ax-AI were similar to 
those based on prospective observation of HIV 
seroconversion [24]. However, incidence rate estimates 
derived via Ax-AI alone were substantially higher than those 
based on observed HIV seroconversion. The present analysis 
focused on risk factor estimation using STARHS plus 
behavioral interview data. Risk factor estimates (adjusted 
odds ratios) were compared for: 1) prevalent HIV infection; 
2) RI based on three different STARHS RI classifications 
(BED alone, Ax-AI alone, BED/Ax-AI combined) with CD4 
correction (<200 cells/μl excluded from RI); and 3) observed 
HIV seroconversion in the prospective study. 
MATERIALS AND METHODOLOGY 
Study Design and Procedures 
 The study was conducted by Projet Ubuzima, a non-
governmental medical research organization in Kigali, 
Rwanda. Between October 2006 and August 2007, 800 
women participated in the cross-sectional survey with HIV, 
HSV-2 and pregnancy testing. Individuals testing HIV 
positive were further tested with the BED and Ax-AI assays, 
and CD4 cytometry. All women underwent a face-to-face 
interview for demographic and behavioral risk factor 
information. Women were eligible for the cross-sectional 
study if they were: 18 years; at high risk for sexual 
exposure to HIV, defined as having exchanged sex for 
money at least once in the last month and/or currently having 
sex with multiple partners plus having sex at least twice per 
week (all enrolled women self-reported sex work); HIV 
serostatus unknown or last test negative; and willing and able 
to provide written informed consent. 
 Of 608 women identified as HIV-uninfected during the 
cross-sectional survey, 397 (65%) who consented and were 
not pregnant were enrolled consecutively into a prospective 
cohort study. Cohort participants returned for five visits over 
two years for HIV counseling and testing (including condom 
provision), pregnancy and HSV-2 testing, and face-to-face 
interviewing. Twelve-month retention was 96%, and median 
follow-up was 689 days (range: 0-836). Specimens from 
women who became HIV infected during follow-up were 
tested by CD4 cytometry. Women who tested positive for 
HIV, HSV-2 or pregnancy were referred for care and 
treatment. All HIV-positive study participants were ART-
naïve. 
 The study was approved by the National Ethics 
Committee and National HIV/AIDS Committee (CNLS) in 
Rwanda, and by Columbia University Medical Center’s 
Institutional Review Board in the United States. 
Laboratory Assessments 
 Blood specimens were tested for HIV by First Response 
(Premier Medical Corporation, India) and Uni-Gold (Trinity 
Biotech Plc, Ireland) rapid tests, with Capillus HIV-1/HIV-2 
Rapid Test (Trinity Biotech Plc, Ireland) as a tie-breaker. 
HIV rapid test-positive results were confirmed by Murex 
HIV Ag/Ab Combination ELISA (Abbott Laboratories, 
Germany), and then tested further by CD4 cytometry at 
Rwanda’s national reference laboratory in Kigali. HSV-2 
infection was assessed by HerpeSelect 2 ELISA (Focus 
Technologies, USA) and pregnancy by the Fortress hCG test 
(Fortress Diagnostics, UK). HSV-2, pregnancy, HIV rapid 
and ELISA testing was done onsite at Projet Ubuzima. 
 Blood specimens from HIV-positive survey participants 
were tested by the BED and Ax-AI assays. BED testing was 
performed onsite following standard procedures as described 
in the literature [23, 24] and manufacturer’s package insert 
(Calypte
®
 Biomedical Corporation, Oregon, USA), using a 
cutoff of OD-n 0.8 to indicate RI. Ax-AI testing was 
performed by the Pediatric HIV Research Unit in South 
Africa using an unmodified AxSYM HIV-1/2gO ELISA 
(Abbott, USA), and following procedures described in the 
literature [13], with an avidity index 0.85 indicating RI 




 In the cross-sectional sample, a prevalent HIV case was a 
participant who tested positive on HIV rapid tests (with 
ELISA confirmation), irrespective of STARHS results. 
Prevalent cases represent undiagnosed HIV infections only 
in the sampled population, given the eligibility criterion of 
having an unknown HIV serostatus or a negative last HIV 
test. In analyses of BED and Ax-AI separately, RI cases 
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were HIV-positive participants who were classified as RI by 
the BED or Ax-AI, respectively. In analyses using BED and 
Ax-AI combined, we counted as RI cases only those survey 
participants who tested HIV positive and were then classified 
as RI by both BED and Ax-AI assays. Additionally, 
individuals with CD4<200 cells/μl were considered probable 
LTI cases regardless of STARHS results, and so individuals 
classified as RI but with CD4<200 cells/μl were removed 
from analyses of recent infection [37], but examined in 
sensitivity analyses. In the prospective sample, HIV 
seroconversion date was estimated as the midpoint between 
the last negative and first positive HIV test (±3-month 
interval). 
Analysis 
 For the cross-sectional sample, odds ratios (OR) and 95% 
confidence intervals (CI) for prevalent HIV (based on HIV 
rapid testing), and for RI (based on STARHS classifications) 
were derived from logistic regression models, with HIV-
negative participants as the comparison group for each. All OR 
are age-adjusted, and factors with P<0.05 were considered 
statistically significant. 
 For the prospective sample, Cox proportional hazards 
regression was used to estimate hazard ratios (HR) and 95% 
CI for HIV seroconversion. Only results for baseline 
covariates are presented to enable comparison with logistic 
models for the cross-sectional sample. All HR are age-
adjusted, and factors with P<0.05 were considered 
statistically significant. 
 We qualitatively compared the direction, magnitude, and 
statistical significance of putative risk factors for: 1) 
prevalent HIV; 2) RI based on three different STARHS 
classifications (BED alone, Ax-AI alone, and BED/Ax-AI 
combined); and 3) prospectively observed seroconversion in 
the cohort study. All statistical tests are two-sided. Data were 




 HIV-positive survey participants (N=192), HIV-negative, 
non-enrolled survey participants (N=211), and prospective 
cohort participants (N=397) were similar on most 
sociodemographic characteristics (Table 1). Median age in 
the three groups was 27 (IQR: 23-32), 25 (23-31), and 24 
(22-28), respectively. Approximately one-fifth of 
participants in all groups (23%, 17%, and 22%) had no 
formal schooling. Most participants (93%, 91%, and 91%) 
reported currently using at least one contraceptive method, 
with about three-quarters (72%, 72%, and 75%) reporting 
condom use by their last sex partner. The majority of women 
in the three groups had 1-2 pregnancies during their 
lifetimes. The proportion currently breastfeeding varied 
across the groups (21%, 45% and 55%). 
Prevalent, Recent, and Incident HIV Infections 
 In the cross-sectional survey, 192 women tested HIV 
positive for a prevalence of 24.0% (95% CI, 21.0-27.0). 
Among 190 prevalent HIV cases with BED/Ax-AI results, 
36 (19%) were classified as RI by BED, and 56 (30%) as RI 
by Ax-AI. Twenty-three participants (12%) were classified  
as RI by both assays; 121 (64%) as LTI by both assays; and 
46 (24%) were classified discordantly on the assays (i.e., 
recent on BED and long-term on Ax-AI, or vice versa). Two 
individuals concordant for RI on the assays (9%) had 
CD4<200 cells/μl, indicating possible LTI. Nineteen of the 
397 cohort participants (5%) seroconverted for HIV during 
686.5 person-years of follow-up (2.8 per 100 person-years). 
Risk Factors for Prevalent and Recent HIV Infection in 
the Cross-Sectional Sample 
 Table 2 presents age-adjusted odds ratios (aOR) for putative 
risk factors in the cross-sectional sample for prevalent HIV 
infection (by HIV rapid testing and ELISA), and recent 
infection (by STARHS assays, alone or in combination), 
compared to HIV-negative participants. Only number of sex 
partners in the prior 3 months (60-75 versus 76-120, aOR 5.1, 
95% CI (1.0, 25.1)) was associated with RI (by BED/Ax-AI 
combined), but not prevalent HIV infection. Two factors—
HSV-2 co-infection and having recently sought treatment for a 
sexually transmitted infection (STI)—were positively associated 
with both prevalent infection (aOR 8.4 (4.8, 14.7) and 2.1 (1.3, 
3.3), respectively) and RI by BED/Ax-AI combined (aOR 17.9 
(2.4, 134.7), and 3.9 (1.4, 10.4), respectively). Several factors 
were associated (either positively or negatively) with prevalent 
HIV, but not RI (by BED/Ax-AI combined), including: history 
of forced sex (aOR 2.2 (1.5, 3.1)); current breastfeeding (aOR 
0.3 (0.2, 0.4)); being widowed (aOR 1.7 (1.0, 2.8)); lifetime 
HIV testing history ( 2 tests versus none, aOR 0.3 (0.2, 0.5); 1 
test versus none, aOR 0.6 (0.4, 0.9)); regular alcohol 
consumption (aOR 1.5 (1.1, 2.2)); and history of imprisonment 
(aOR 1.8 (1.3, 2.6)). Education level, number of lifetime 
pregnancies, condom use, frequency of vaginal sex, and marital 
status were not significantly associated with prevalent or recent 
HIV infection. 
 Table 2 also presents risk factors for recent HIV infection 
on the BED and Ax-AI assays analyzed separately. HSV-2 
seropositivity and recent STI treatment were consistently 
identified as risk factors in both models. However, the Ax-
AI method identified two additional factors—district of 
residence and HIV testing history ( 2 times versus never)—
that were not significant in the BED model. Risk factor 
associations for LTI, which excludes recent infections, and 
prevalent HIV, which includes RI, were nearly identical to 
one another (data not shown). 
Comparison of Risk Factors Associated with STARHS 
Results to those Identified via Prospectively Observed 
Seroconversion 
 In the prospective cohort, having been HIV tested 2 
times versus never in one’s lifetime and HIV testing within 
the past 6 months were positively associated with HIV 
seroconversion (Table 2). Having had two versus 4 lifetime 
pregnancies was borderline statistically significant (aOR 8.0 
(1.0, 65.4), P=0.05). None of the risk factors for prospective 
seroconversion was also identified as a risk factor for RI (by 
BED/Ax-AI combined) in the cross-sectional sample. 
DISCUSSION 
 In these samples of urban Rwandan FSW, we found 
mixed agreement between three different methods of  
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Table 1. Demographic and Behavioral Characteristics
a
 of Female Sex Workers in Kigali, Rwanda 
 
 




HIV-Negative, Non-Enrolled  
Survey Participants  
(N=211) 
N (%) 
Prospective Cohort Participants 
(N=397) 
N (%) 
Median age, in years (IQR)*** 























Education level: * 
No formal schooling 
Some primary school 
Completed primary school 
















Median weekly income in Rwandan francsb (IQR)*** 15,000 (8,000-23,000) 20,000 (12,000-33,000) 12,000 (7,000-20,000) 
Currently using family planning method 179 (93) 191 (91) 362 (91) 
























Currently breastfeeding* 40 (21) 95 (45) 219 (55) 
Marital statusc: 























At last sexc: 
Received money or gift from partner** 
Partner used a condom 
Used vaginal lubricant** 
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assessing risk factors for HIV infection, even when the HIV 
incidence rates based on BED alone, BED/Ax-AI combined, 
and observed seroconversion were relatively similar [24]. 
We identified a number of putative and protective risk 
factors for prevalent HIV infection using conventional 
serologic testing. We identified only a few risk factors for 
recent infection using two STARHS assays (BED and Ax-
AI) with three different classifications. Although two of the 
three factors (HSV-2 coinfection and recent STI treatment) 
were also risk factors for prevalent infection, the third factor 
(number of sex partners in the past 3 months) was only 
identified by the STARHS classification that best classified 
recent HIV infection in this sample [24], the BED/Ax-AI 
combined. Finally, risk factors for recent infection (by single 
or combined STARHS assays) were different from those 
associated with HIV seroconversions in the prospective 
cohort. 
 Decisions by ministries of health to institutionalize the 
use of STARHS for incidence surveillance—specifically, to 
generate HIV incidence estimates and identify risk factors 
for recently acquired infection from cross-sectional samples 
in settings such as Kigali, Rwanda—hinge on the 
epidemiologic utility of the approach. We defined 
epidemiologic utility, in part, as the ability of an assay or 
algorithm to distinguish risk factors for recent from longer-
term infection when such differences exist. From the  
 
perspective of epidemiologic utility, factors associated with 
prevalent infection differed substantially from those 
associated with recent infection in this sample. 
 Our findings are consistent with at least two plausible 
scenarios in this specific population of Rwandan female sex 
workers. First, in reality, there may be differences between 
factors associated with incident versus prevalent HIV 
infection in this population, for example if HIV transmission 
dynamics in this group have recently begun to evolve. 
Alternatively, true similarities in the risk factor profile for 
incident and prevalent infection in this population could have 
been masked in our analyses by misclassification on the 
assays or low statistical power to identify risk factors as 
statistically significant. However, prevalent infections, recent 
infections by STARHS, and prospectively observed 
seroconversions measure varying stages of infection in 
different time periods, and so risk factors could be expected 
to be different when the epidemic is evolving. Nonetheless, 
the use of epidemiologic utility, including assay sensitivity 
and specificity, as a metric of STARHS is conceptually and 
methodologically important, particularly given the intent to 
use STARHS as an epidemiological tool at the population 
level, not at the individual level [38]. Future studies, ideally 
with more statistical power, are needed to further examine 
the epidemiologic utility among at-risk sub-Saharan African 
populations. 
 
(Table 1) contd….. 
 




HIV-Negative, Non-Enrolled  
Survey Participants  
(N=211) 
N (%) 
Prospective Cohort Participants 
(N=397) 
N (%) 
























Ever had forced sex** 72 (38) 55 (26) 76 (19) 
























HIV testing in the last 6 months 4 (2) 22 (11) 57 (15) 
 1 Genital symptome in past month 50 (26) 50 (24) 78 (20) 
Sought treatment for STI symptom in last 3 months 34 (18) 22 (10) 32 (8) 
Drink alcohol regularly 







Ever imprisoned 89 (47)  77 (37) 150 (38) 
Abbreviations: IQR = Inter-quartile range ; HIV = Human Immunodeficiency Virus;  STI = Sexually transmitted infections. 
*P < 0.05; **P < 0.01; ***P < 0.001 for comparisons between cohort participants and HIV-negative, non-enrolled survey participants. 
aSample sizes for different questions may vary slightly from N=800 based on missing responses. 
b1 US Dollar=approximately 555 Rwandan francs. 
cMultiple responses allowed. 
dA steady partner is a regular sex partner with whom the woman has sex more often than with other partner(s), but does not live with and is not married to. 
eIncludes: genital itching, burning, rash, pain; abnormal vaginal discharge, odor, or bleeding (non-menstrual); pain or difficulty urinating; genital ulcers, sores or blisters; pain during 
sex; acute lower abdominal pain; other genital symptoms. 
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Table 2. Risk Factors for Prevalent HIV Infection, Recent HIV Infection
a
 (by BED-CEIA Assay and Ax-AI, Separately and 




RI by BED Alone 
(N, RI=31) 
RI by Ax-AI Alone 
(N, RI=50) 























0.8 (0.5, 1.2) 
--REF-- 
1.9 (1.2, 3.1) 
1.8 (1.1, 3.0) 
 
1.3 (0.5, 3.5) 
--REF-- 
2.0 (0.6, 6.9) 
3.3 (1.1, 10.2) 
 
1.1 (0.5, 2.2) 
--REF-- 
1.8 (0.7, 4.5) 
1.9 (0.7, 4.8) 
 
1.1 (0.4, 3.1) 
--REF-- 
0.8 (0.2, 4.1) 
0.9 (0.2, 4.8) 
 
1.0 (0.3, 3.1) 
--REF-- 
1.9 (0.6, 6.2) 
undefined 






2.0 (1.3, 3.0) 
3.1 (2.0, 4.8) 
 
-- REF -- 
2.2 (0.9, 5.4) 
1.8 (0.6, 4.9) 
 
-- REF -- 
2.4 (1.1, 5.3) 
3.2 (1.4, 7.2) 
 
-- REF -- 
2.1 (0.7, 6.2) 
1.8 (0.5, 6.0) 
 
-- REF -- 
0.7 (0.2, 2.1) 
1.1 (0.4, 3.4) 
Education level: 
No formal schooling 
Some primary school 
Completed primary school 
Secondary school (some/completed) 
 
--REF-- 
0.9 (0.6, 1.4) 
0.8 (0.5, 1.3) 
0.7 (0.4, 1.3) 
 
--REF-- 
1.5 (0.5, 4.4) 
1.1 (0.3, 3.5) 
1.6 (0.4, 5.6) 
 
--REF-- 
1.1 (0.5, 2.4) 
1.1 (0.5, 2.7) 
1.4 (0.5, 3.8) 
 
--REF-- 
1.8 (0.5, 6.5) 
1.3 (0.3, 5.4) 
1.1 (0.2, 6.4) 
 
--REF-- 
0.9 (0.3, 2.9) 
2.5 (0.6, 10.2) 
undefined 







1.9 (0.9, 4.2) 
1.5 (0.9, 2.7) 
1.5 (0.8, 2.5) 
1.1 (0.6, 1.9) 
--REF-- 
 
0.9 (0.2, 4.8) 
0.3 (0.1, 1.3) 
1.2 (0.4, 3.4) 
0.8 (0.3, 2.4) 
--REF-- 
 
1.9 (0.5, 6.7) 
0.9 (0.3, 2.7) 
1.4 (0.5, 3.5) 
0.9 (0.3, 2.4) 
--REF-- 
 
0.9 (0.1, 5.7) 
0.2 (0.1, 1.3) 
1.0 (0.3, 3.9) 




1.2 (0.1, 14.7) 
8.0 (1.0, 65.4) 
4.7 (0.5, 41.1) 
--REF-- 
Currently breastfeeding 0.3 (0.2, 0.4) 0.8 (0.4, 1.8) 0.7 (0.3, 1.5) 0.9 (0.4, 2.1) 1.6 (0.6, 4.3) 
Marital statusc: 





0.9 (0.7, 1.3) 
0.7 (0.4, 1.1) 
1.7 (1.0, 2.8) 
1.0 (0.7, 1.4) 
 
0.8 (0.4, 1.7) 
0.9 (0.3, 2.5) 
1.3 (0.4, 4.0) 
0.9 (0.4, 2.2) 
 
1.1 (0.6, 1.9) 
0.7 (0.3, 1.7) 
1.5 (0.6, 3.7) 
1.1 (0.5, 2.2) 
 
1.1 (0.5, 2.8) 
1.0 (0.3, 3.4) 
1.2 (0.2, 5.8) 
1.0 (0.3, 3.0) 
 
0.6 (0.2, 1.8) 
0.5 (0.1, 4.2) 
undefined 
2.1 (0.6, 7.5) 
At last sexc: 
Received money/gift from partner 
Partner used a condom 
Vaginal cleansing beforehand 
 
1.1 (0.6, 2.1) 
0.9 (0.6, 1.3) 
1.6 (1.2, 2.2) 
 
1.1 (0.3, 4.8) 
0.6 (0.3, 1.4) 
1.5 (0.7, 3.1) 
 
1.1 (0.3, 4.8) 
1.2 (0.6, 2.5) 
1.6 (0.9, 2.8) 
 
0.7 (0.2, 3.2) 
0.4 (0.2, 1.1) 
1.9 (0.8, 4.6) 
 
1.1 (0.2, 8.1) 
1.0 (0.9, 1.1) 
0.8 (0.3, 1.9) 







0.7 (0.4, 1.3) 
1.0 (0.6, 1.5) 
1.0 (0.6, 1.6) 
--REF-- 
0.8 (0.4, 1.5) 
 
1.7 (0.5, 6.1) 
2.7 (0.9, 8.4) 
1.5 (0.4, 5.6) 
--REF-- 
0.5 (0.1, 4.6) 
 
0.8 (0.3, 1.9) 
1.1 (0.5, 2.3) 
0.8 (0.4, 2.0) 
--REF-- 
0.5 (0.1, 1.9) 
 
2.3 (0.4, 13.0) 
3.6 (0.8, 16.6) 
1.9 (0.4, 10.7) 
--REF-- 
1.0 (0.1, 11.1) 
 
0.4 (0.1, 1.4) 
0.4 (0.1, 1.6) 
0.2 (0.02, 1.4) 
--REF-- 
1.1 (0.2, 6.2) 







1.3 (0.7, 2.4) 
0.9 (0.5, 1.6) 
1.5 (0.9, 2.5) 
--REF-- 
1.0 (0.6, 1.6) 
 
3.2 (0.9, 11.7) 
1.5 (0.4, 5.9) 
2.7 (0.8, 9.4) 
--REF-- 
1.0 (0.3, 3.3) 
 
1.1 (0.3, 3.7) 
1.2 (0.5, 3.4) 
2.2 (0.9, 5.6) 
--REF-- 
1.1 (0.4, 2.5) 
 
3.5 (0.6, 21.5) 
2.6 (0.5, 14.5) 
5.1 (1.0, 25.1) 
--REF-- 
0.9 (0.6, 1.4) 
 
2.6 (0.8, 8.7) 











0.7 (0.4, 1.2) 
1.1 (0.7, 1.8) 
0.9 (0.6, 1.5) 
--REF-- 
0.6 (0.3, 1.4) 
 
1.7 (0.5, 5.9) 
2.2 (0.7, 7.1) 
1.0 (0.3, 3.7) 
--REF-- 
0.6 (0.1, 5.7) 
 
0.8 (0.3, 2.0) 
1.3 (0.6, 2.9) 
0.7 (0.3, 1.7) 
--REF-- 
0.7 (0.2, 2.8) 
 
2.1 (0.4, 11.2) 
3.1 (0.7, 14.7) 
1.2 (0.2, 6.9) 
--REF-- 
1.1 (0.1, 12.8) 
 
0.5 (0.1, 1.6) 
0.6 (0.2, 2.2) 
0.5 (0.1, 2.3) 
--REF-- 
undefined 
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 We conducted a number of sensitivity analyses of our 
data. Specifically, adjustment of STARHS results from 
bivariable models with CD4 count data (with individuals 
with CD4<200 cells/μl excluded as probable LTI) did not 
change inference regarding the existence of associations for 
specific risk factors. Additional sensitivity analyses (data not 
shown) showed that excluding persons classified as RI with 
CD4 counts up to 500 cells/μl did not alter risk factor 
findings. Misclassification rates may change with different 
study populations, for example a less healthy population 
with a different CD4 count distribution; misclassification of 
individuals with LTI and high CD4 counts is also possible. 
In our study, it is possible that greater specificity in the risk 
factor analysis from use of the BED and Ax-AI assays 
combined reduced the potential impact of CD4 adjustment. 
Indeed, the combined testing algorithm appeared to perform 
better for risk factor identification in the cross-sectional 
sample than the assays alone, particularly compared with the 
Ax-AI method alone. For example, the two additional risk 
factors for RI identified by the Ax-AI method alone were 
identified as risk factors for prevalent infection, which 
reflects the substantial misclassification of individuals with 
longer-term infection as RI by the Ax-AI method in this 
population [24]. CD4 adjustment may have a greater impact 
in studies using only a single assay versus a combined 
algorithm, and such studies should therefore conduct CD4  
 
testing if possible. Finally, conducting STARHS studies 
among treatment-naïve individuals will help avoid 
misinterpretation of STARHS results with CD4 adjustment. 
 Comparison of the risk factors identified using the cross-
sectional methods against those identified using the gold-
standard prospective method may aid the interpretation of 
cross-sectional risk factor data, however caution when 
making such a comparison is warranted. In this study, there 
was no overlap between risk factors for recent infection in 
the cross-sectional sample and predictors of HIV 
seroconversion in the prospective sub-sample. Limited 
statistical power for identifying significant factors could 
have affected agreement between the methods, as there were 
relatively few events in both the RI and seroconversion 
models. However, important differences between the sub-
sample of women who were eligible and agreed to 
participate in the prospective cohort study and HIV-negative 
survey participants not enrolled in the cohort may also 
contribute to the discordance. For example, HIV-negative 
cohort participants were younger, more likely to be 
breastfeeding, less likely to have a history of forced sex, and 
had more recently initiated sex work than HIV-negative non-
enrolled women, all factors associated with HIV risk. 
Furthermore, changes over time in cohort participants’ risk 
level (for example, because of the effect of prevention 
interventions or the Hawthorne effect), or unknown factors  
 
(Table 2) contd….. 
Prevalent HIV 
(N=192) 
RI by BED Alone 
(N, RI=31) 
RI by Ax-AI Alone 
(N, RI=50) 
























1.0 (0.6, 1.7) 
0.4 (0.2, 0.8) 
1.2 (0.7, 1.9) 
0.8 (0.5, 1.4) 
--REF-- 
 
1.9 (0.7, 5.6) 
0.8 (0.2, 2.8) 
0.6 (0.1, 2.3) 
0.8 (0.3, 2.6) 
--REF-- 
 
1.5 (0.7, 3.6) 
0.3 (0.1, 1.1) 
1.0 (0.4, 2.6) 
0.7 (0.2, 1.7) 
--REF-- 
 
4.2 (0.9, 19.4) 
1.0 (0.1, 6.9) 
1.9 (0.3, 10.7) 
1.4 (0.2, 8.8) 
--REF-- 
 
1.8 (0.6, 5.3) 




Ever had forced sex 2.2 (1.5, 3.1) 1.7 (0.8, 3.7) 1.8 (1.0, 3.4) 2.3 (0.9, 5.7) 0.8 (0.2, 2.6) 






0.6 (0.4, 0.9) 
0.3 (0.2, 0.5) 
 
--REF-- 
0.6 (0.3, 1.5) 
0.6 (0.3, 1.5) 
 
--REF-- 
0.6 (0.3, 1.2) 
0.4 (0.2, 0.9) 
 
--REF-- 
0.6 (0.2, 1.9) 
1.1 (0.4, 3.0) 
 
--REF-- 
4.8 (0.6, 41.2) 
12.9 (1.7, 98.9) 
HIV tested in last 6 months 0.2 (0.1, 0.4) 0.2 (0.1, 1.8) 0.1 (0.01, 1.0) 0.3 (0.04, 2.2) 3.4 (1.2, 9.1) 
Sought STI treatment in last 3 months 2.1 (1.3, 3.3) 2.8 (1.2, 6.9) 3.1 (1.5, 6.2) 3.9 (1.4, 10.4) 0.6 (0.1, 4.3) 
Drink alcohol regularly 1.5 (1.1, 2.2) 1.1 (0.5, 2.3) 1.3 (0.7, 2.3) 0.7 (0.3, 1.7) 1.3 (0.5, 3.3) 
Ever imprisoned 1.8 (1.3, 2.6) 0.9 (0.4, 2.0) 1.2 (0.6, 2.2) 0.6 (0.2, 1.7) 1.4 (0.5, 3.5) 
HSV-2 seropositive (baseline) 8.4 (4.8, 14.7) 3.9 (1.5, 10.5) 9.1 (3.2, 25.9) 17.9 (2.4, 134.7) 1.4 (0.5, 3.8) 
Pregnant (baseline) 0.7 (0.3, 1.3) 0.8 (0.2, 3.5) 0.7 (0.2, 2.5) 1.1 (0.3, 5.0) NA 
Abbreviations: OR=odds ratio; HR=hazard ratio; CI=confidence interval; HIV=Human Immunodeficiency Virus; RI=recent infection; STI=sexually transmitted infection; NA=not 
applicable. 
Bolded effect estimates have P< 0.05. 
a Participants with CD4<200 removed from RI classification, considered probable long-term HIV infection. 
b Sample sizes for different questions may vary slightly from the total N based on missing responses. 
c Multiple responses allowed. 
d A steady partner is a regular sex partner with whom the woman has sex more often than with other sex partner(s), but does not live with and is not married to. 
e Categories for age-adjusted HR’s for prospective cohort are: 3-30; 31-75; and 76 partners (referent group is 76). 
f Categories for age-adjusted HR’s for prospective cohort are: 1; 2-3; and 4 years (referent group is 4). 
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Table 3. Comparison of Demographic and Risk Characteristics of HIV Seroconverters (N=19) and HIV-Negative Participants 







Cohort Participants  
(N=378) 
N (%) 
Median age (IQR) 


























Currently breastfeeding 12 (63) 207 (55) 
Lifetime no. pregnancies: 














Male condom use at last sex 16 (84) 280 (74) 
Current hormonal contraception use 5 (26) 67 (18) 
1 Genital symptom in past month  6 (32) 72 (19) 





































































HIV tested in prior 6 months 6 (32) 51 (14) 
HSV-2 seropositive at baseline 12 (67) 202 (56) 
Median days from enrollment to seroconversion (range) 269 (86-768) NA 
Abbreviations: IQR = Inter-quartile range; HIV = Human Immunodeficiency Virus; NA = Not applicable.  
Includes: genital itching, burning, rash, pain; abnormal vaginal discharge, odor, or bleeding (non-menstrual); pain or difficulty urinating; genital ulcers, sores or blisters; pain during 
sex; acute lower abdominal pain; other genital symptoms. 
¥2 participants missing response, N=17. 
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causing misclassification on the assays, could also have 
contributed to discordance between cross-sectional and 
prospective risk factor findings. Most HIV seroconversions 
in the cohort occurred early during follow-up, and women 
who seroconverted differed from women who remained 
HIV-negative during follow-up on several potentially 
important factors. For example, seroconverters had spent 
fewer years in sex work, reported more frequent sex, had 
higher HSV-2 seroprevalence at baseline, and reported more 
genital symptoms in the month prior to enrollment (Table 3). 
Additional study limitations are noted. Due to sample size 
(specifically, too few outcomes), we could only adjust for 
age and thus were unable to conduct a full multivariate 
analysis. This could have resulted in uncontrolled 
confounding, complicating comparisons between prospective 
and cross-sectional samples. Measurement error in covariates 
and bias due to unmeasured confounding could have affected 
risk factor findings. 
 This study also has several strengths and provides new 
insights. The use of two STARHS assays contributed 
important information about the assays’ combined and 
individual performance in a high-prevalence population. The 
combined cross-sectional and prospective design, and 
extensive interview data, enabled in-depth exploration, 
triangulation, and comparison of risk factors for prevalent 
and recently acquired HIV infection in multiple samples. 
This in turn allowed us to explore an important dimension of 
the epidemiologic utility of HIV incidence assays, namely 
risk factor detection. Finally, availability of CD4 count data 
aided interpretation and enabled important sensitivity 
analyses. 
CONCLUSION 
 In this selected high-risk group, factors associated with 
incident HIV infection appeared to differ from those 
associated with prevalent infection. More studies evaluating 
the ability of STARHS to detect risk factors when combined 
with survey data, alongside the validity of STARHS-based 
incidence estimates, are needed to further establish the 
epidemiologic utility of the approach for incidence 
surveillance. Such studies are especially needed in sub-
Saharan Africa where there is very limited experience with 
STARHS, and where the potential impact of an alternative to 
prospective measurement of HIV incidence is greatest [5]. 
Specifically, such investigations should be conducted in 
populations in which risk factors for HIV incidence and 
prevalence are known or expected to differ, as well as 
populations with more diversity in risk factors (e.g., 
population-based samples). Despite persisting concerns 
about the validity of particular STARHS assays, the results 
of this study underscore the potential value of the approach 
in identifying and distinguishing groups in need of HIV 
prevention services when combined with complementary 
risk group and behavioral information. 
 Public health officials in Rwanda might consider 
incorporating STARHS into the next Demographic and 
Health Survey-Plus to conduct similar analyses on the 
national level and across population groups, as has been 
done successfully in Uganda [37] and South Africa [18]. 
Further evaluations of STARHS data in Rwanda and across 
diverse settings, as well as development of assays with 
improved validity, will strengthen the argument to 
incorporate HIV incidence surveillance into routine HIV 
surveillance. 
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